ID   MP2K2_HUMAN             Reviewed;         400 AA.
AC   P36507;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 1.
DT   12-OCT-2022, entry version 236.
DE   RecName: Full=Dual specificity mitogen-activated protein kinase kinase 2;
DE            Short=MAP kinase kinase 2;
DE            Short=MAPKK 2;
DE            EC=2.7.12.2 {ECO:0000269|PubMed:10409742};
DE   AltName: Full=ERK activator kinase 2;
DE   AltName: Full=MAPK/ERK kinase 2;
DE            Short=MEK 2;
GN   Name=MAP2K2; Synonyms=MEK2, MKK2, PRKMK2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8388392; DOI=10.1016/s0021-9258(18)82142-1;
RA   Zheng C.-F., Guan K.-L.;
RT   "Cloning and characterization of two distinct human extracellular signal-
RT   regulated kinase activator kinases, MEK1 and MEK2.";
RL   J. Biol. Chem. 268:11435-11439(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Muscle, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   PROTEIN SEQUENCE OF 40-51; 53-61; 64-100; 102-112; 164-172; 194-205;
RP   265-297; 362-371 AND 389-397, PHOSPHORYLATION AT THR-394, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Colon carcinoma;
RA   Bienvenut W.V., Zebisch A., Kolch W.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [4]
RP   PROTEIN SEQUENCE OF 210-231, INACTIVATION BY YERSINIA YOPJ (MICROBIAL
RP   INFECTION), PHOSPHORYLATION AT SER-222 AND SER-226, ACETYLATION AT SER-222
RP   AND SER-226, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=17116858; DOI=10.1073/pnas.0608995103;
RA   Mittal R., Peak-Chew S.Y., McMahon H.T.;
RT   "Acetylation of MEK2 and I kappa B kinase (IKK) activation loop residues by
RT   YopJ inhibits signaling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:18574-18579(2006).
RN   [5]
RP   CLEAVAGE BY ANTHRAX LETHAL FACTOR.
RX   PubMed=9563949; DOI=10.1126/science.280.5364.734;
RA   Duesbery N.S., Webb C.P., Leppla S.H., Gordon V.M., Klimpel K.R.,
RA   Copeland T.D., Ahn N.G., Oskarsson M.K., Fukasawa K., Paull K.D.,
RA   Vande Woude G.F.;
RT   "Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor.";
RL   Science 280:734-737(1998).
RN   [6]
RP   PROTEIN SEQUENCE OF 39-49; 52-61 AND 352-361, CATALYTIC ACTIVITY, COFACTOR,
RP   INTERACTION WITH KSR1, SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT
RP   SER-222.
RX   PubMed=10409742; DOI=10.1128/mcb.19.8.5523;
RA   Stewart S., Sundaram M., Zhang Y., Lee J., Han M., Guan K.L.;
RT   "Kinase suppressor of Ras forms a multiprotein signaling complex and
RT   modulates MEK localization.";
RL   Mol. Cell. Biol. 19:5523-5534(1999).
RN   [7]
RP   CLEAVAGE BY ANTHRAX LETHAL FACTOR.
RX   PubMed=11104681; DOI=10.1042/bj3520739;
RA   Vitale G., Bernardi L., Napolitani G., Mock M., Montecucco C.;
RT   "Susceptibility of mitogen-activated protein kinase kinase family members
RT   to proteolysis by anthrax lethal factor.";
RL   Biochem. J. 352:739-745(2000).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-293 AND SER-295, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-394 AND THR-396, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [12]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [13]
RP   INTERACTION WITH SGK1.
RX   PubMed=19447520; DOI=10.1016/j.jhep.2009.02.027;
RA   Won M., Park K.A., Byun H.S., Kim Y.R., Choi B.L., Hong J.H., Park J.,
RA   Seok J.H., Lee Y.H., Cho C.H., Song I.S., Kim Y.K., Shen H.M., Hur G.M.;
RT   "Protein kinase SGK1 enhances MEK/ERK complex formation through the
RT   phosphorylation of ERK2: implication for the positive regulatory role of
RT   SGK1 on the ERK function during liver regeneration.";
RL   J. Hepatol. 51:67-76(2009).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-295 AND THR-394, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-394 AND THR-396, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [19]
RP   INTERACTION WITH GLS.
RX   PubMed=22538822; DOI=10.1073/pnas.1116573109;
RA   Thangavelu K., Pan C.Q., Karlberg T., Balaji G., Uttamchandani M.,
RA   Suresh V., Schuler H., Low B.C., Sivaraman J.;
RT   "Structural basis for the allosteric inhibitory mechanism of human kidney-
RT   type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in
RT   cancer cell metabolism.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:7705-7710(2012).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-394 AND THR-396, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-23 AND THR-396, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [22]
RP   FUNCTION, AND INTERACTION WITH BRAF AND KSR1.
RX   PubMed=29433126; DOI=10.1038/nature25478;
RA   Lavoie H., Sahmi M., Maisonneuve P., Marullo S.A., Thevakumaran N., Jin T.,
RA   Kurinov I., Sicheri F., Therrien M.;
RT   "MEK drives BRAF activation through allosteric control of KSR proteins.";
RL   Nature 554:549-553(2018).
RN   [23]
RP   VARIANT CFC4 CYS-57.
RX   PubMed=16439621; DOI=10.1126/science.1124642;
RA   Rodriguez-Viciana P., Tetsu O., Tidyman W.E., Estep A.L., Conger B.A.,
RA   Cruz M.S., McCormick F., Rauen K.A.;
RT   "Germline mutations in genes within the MAPK pathway cause cardio-facio-
RT   cutaneous syndrome.";
RL   Science 311:1287-1290(2006).
RN   [24]
RP   VARIANTS CFC4 VAL-57 AND HIS-134.
RX   PubMed=18042262; DOI=10.1111/j.1399-0004.2007.00931.x;
RA   Schulz A.L., Albrecht B., Arici C., van der Burgt I., Buske A.,
RA   Gillessen-Kaesbach G., Heller R., Horn D., Hubner C.A., Korenke G.C.,
RA   Konig R., Kress W., Kruger G., Meinecke P., Mucke J., Plecko B.,
RA   Rossier E., Schinzel A., Schulze A., Seemanova E., Seidel H., Spranger S.,
RA   Tuysuz B., Uhrig S., Wieczorek D., Kutsche K., Zenker M.;
RT   "Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous
RT   and Costello syndrome.";
RL   Clin. Genet. 73:62-70(2008).
RN   [25]
RP   VARIANT CFC4 GLN-128, AND CHARACTERIZATION OF VARIANT CFC4 GLN-128.
RX   PubMed=20358587; DOI=10.1002/ajmg.a.33342;
RA   Rauen K.A., Tidyman W.E., Estep A.L., Sampath S., Peltier H.M., Bale S.J.,
RA   Lacassie Y.;
RT   "Molecular and functional analysis of a novel MEK2 mutation in cardio-
RT   facio-cutaneous syndrome: transmission through four generations.";
RL   Am. J. Med. Genet. A 152:807-814(2010).
CC   -!- FUNCTION: Catalyzes the concomitant phosphorylation of a threonine and
CC       a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases.
CC       Activates the ERK1 and ERK2 MAP kinases (By similarity). Activates BRAF
CC       in a KSR1 or KSR2-dependent manner; by binding to KSR1 or KSR2 releases
CC       the inhibitory intramolecular interaction between KSR1 or KSR2 protein
CC       kinase and N-terminal domains which promotes KSR1 or KSR2-BRAF
CC       dimerization and BRAF activation (PubMed:29433126).
CC       {ECO:0000250|UniProtKB:Q63932, ECO:0000269|PubMed:29433126}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.12.2;
CC         Evidence={ECO:0000269|PubMed:10409742};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.12.2; Evidence={ECO:0000269|PubMed:10409742};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.12.2;
CC         Evidence={ECO:0000269|PubMed:10409742};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:10409742};
CC   -!- SUBUNIT: Interacts with MORG1 (By similarity). Interacts with SGK1
CC       (PubMed:19447520). Interacts with KSR1 (PubMed:10409742). Interacts
CC       with KSR1 and BRAF; the interaction with KSR1 mediates KSR1-BRAF
CC       dimerization (PubMed:29433126). Interacts with GLS (PubMed:22538822).
CC       {ECO:0000250|UniProtKB:Q63932, ECO:0000269|PubMed:10409742,
CC       ECO:0000269|PubMed:19447520, ECO:0000269|PubMed:22538822,
CC       ECO:0000269|PubMed:29433126}.
CC   -!- INTERACTION:
CC       P36507; P05067: APP; NbExp=3; IntAct=EBI-1056930, EBI-77613;
CC       P36507; P10398: ARAF; NbExp=9; IntAct=EBI-1056930, EBI-365961;
CC       P36507; Q96II5: ARAF; NbExp=4; IntAct=EBI-1056930, EBI-9383168;
CC       P36507; P15056: BRAF; NbExp=11; IntAct=EBI-1056930, EBI-365980;
CC       P36507; O95273: CCNDBP1; NbExp=3; IntAct=EBI-1056930, EBI-748961;
CC       P36507; Q12959: DLG1; NbExp=10; IntAct=EBI-1056930, EBI-357481;
CC       P36507; P61978-2: HNRNPK; NbExp=3; IntAct=EBI-1056930, EBI-7060731;
CC       P36507; Q8IVT5: KSR1; NbExp=9; IntAct=EBI-1056930, EBI-486984;
CC       P36507; P00540: MOS; NbExp=3; IntAct=EBI-1056930, EBI-1757866;
CC       P36507; P04049: RAF1; NbExp=6; IntAct=EBI-1056930, EBI-365996;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:10409742}. Membrane
CC       {ECO:0000269|PubMed:10409742}; Peripheral membrane protein
CC       {ECO:0000269|PubMed:10409742}. Note=Membrane localization is probably
CC       regulated by its interaction with KSR1. {ECO:0000269|PubMed:10409742}.
CC   -!- PTM: MAPKK is itself dependent on Ser/Thr phosphorylation for activity
CC       catalyzed by MAP kinase kinase kinases (RAF or MEKK1). Phosphorylated
CC       by MAP2K1/MEK1 (By similarity). {ECO:0000250}.
CC   -!- PTM: (Microbial infection) Acetylation of Ser-222 and Ser-226 by
CC       Yersinia YopJ prevents phosphorylation and activation, thus blocking
CC       the MAPK signaling pathway. {ECO:0000269|PubMed:17116858,
CC       ECO:0000269|Ref.3}.
CC   -!- DISEASE: Cardiofaciocutaneous syndrome 4 (CFC4) [MIM:615280]: A form of
CC       cardiofaciocutaneous syndrome, a multiple congenital anomaly disorder
CC       characterized by a distinctive facial appearance, heart defects and
CC       intellectual disability. Heart defects include pulmonic stenosis,
CC       atrial septal defects and hypertrophic cardiomyopathy. Some affected
CC       individuals present with ectodermal abnormalities such as sparse,
CC       friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-
CC       like condition. Typical facial features are similar to Noonan syndrome.
CC       They include high forehead with bitemporal constriction, hypoplastic
CC       supraorbital ridges, downslanting palpebral fissures, a depressed nasal
CC       bridge, and posteriorly angulated ears with prominent helices.
CC       {ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262,
CC       ECO:0000269|PubMed:20358587}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. MAP kinase kinase subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L11285; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; BC000471; AAH00471.1; -; mRNA.
DR   EMBL; BC018645; AAH18645.1; -; mRNA.
DR   CCDS; CCDS12120.1; -.
DR   PIR; A46723; A46723.
DR   RefSeq; NP_109587.1; NM_030662.3.
DR   PDB; 1S9I; X-ray; 3.20 A; A/B=55-400.
DR   PDB; 4H3Q; X-ray; 2.20 A; B=4-16.
DR   PDBsum; 1S9I; -.
DR   PDBsum; 4H3Q; -.
DR   AlphaFoldDB; P36507; -.
DR   SMR; P36507; -.
DR   BioGRID; 111591; 247.
DR   CORUM; P36507; -.
DR   DIP; DIP-29119N; -.
DR   IntAct; P36507; 135.
DR   MINT; P36507; -.
DR   STRING; 9606.ENSP00000262948; -.
DR   BindingDB; P36507; -.
DR   ChEMBL; CHEMBL2964; -.
DR   DrugBank; DB11967; Binimetinib.
DR   DrugBank; DB06616; Bosutinib.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB11689; Selumetinib.
DR   DrugBank; DB08911; Trametinib.
DR   DrugCentral; P36507; -.
DR   GuidetoPHARMACOLOGY; 2063; -.
DR   GlyGen; P36507; 2 sites, 1 O-linked glycan (2 sites).
DR   iPTMnet; P36507; -.
DR   MetOSite; P36507; -.
DR   PhosphoSitePlus; P36507; -.
DR   SwissPalm; P36507; -.
DR   BioMuta; MAP2K2; -.
DR   DMDM; 547915; -.
DR   REPRODUCTION-2DPAGE; IPI00003783; -.
DR   CPTAC; CPTAC-1045; -.
DR   CPTAC; CPTAC-1543; -.
DR   CPTAC; CPTAC-811; -.
DR   CPTAC; CPTAC-812; -.
DR   CPTAC; CPTAC-813; -.
DR   EPD; P36507; -.
DR   jPOST; P36507; -.
DR   MassIVE; P36507; -.
DR   MaxQB; P36507; -.
DR   PaxDb; P36507; -.
DR   PeptideAtlas; P36507; -.
DR   PRIDE; P36507; -.
DR   ProteomicsDB; 55203; -.
DR   Antibodypedia; 3543; 1482 antibodies from 49 providers.
DR   CPTC; P36507; 1 antibody.
DR   DNASU; 5605; -.
DR   Ensembl; ENST00000262948.10; ENSP00000262948.4; ENSG00000126934.15.
DR   GeneID; 5605; -.
DR   KEGG; hsa:5605; -.
DR   MANE-Select; ENST00000262948.10; ENSP00000262948.4; NM_030662.4; NP_109587.1.
DR   UCSC; uc002lzk.4; human.
DR   CTD; 5605; -.
DR   DisGeNET; 5605; -.
DR   GeneCards; MAP2K2; -.
DR   GeneReviews; MAP2K2; -.
DR   HGNC; HGNC:6842; MAP2K2.
DR   HPA; ENSG00000126934; Low tissue specificity.
DR   MalaCards; MAP2K2; -.
DR   MIM; 601263; gene.
DR   MIM; 615280; phenotype.
DR   neXtProt; NX_P36507; -.
DR   OpenTargets; ENSG00000126934; -.
DR   Orphanet; 1340; Cardiofaciocutaneous syndrome.
DR   Orphanet; 638; Neurofibromatosis-Noonan syndrome.
DR   PharmGKB; PA30587; -.
DR   VEuPathDB; HostDB:ENSG00000126934; -.
DR   eggNOG; KOG0581; Eukaryota.
DR   GeneTree; ENSGT00940000153487; -.
DR   InParanoid; P36507; -.
DR   OMA; TEPNICI; -.
DR   OrthoDB; 688282at2759; -.
DR   PhylomeDB; P36507; -.
DR   TreeFam; TF105137; -.
DR   BRENDA; 2.7.12.2; 2681.
DR   PathwayCommons; P36507; -.
DR   Reactome; R-HSA-112411; MAPK1 (ERK2) activation.
DR   Reactome; R-HSA-170968; Frs2-mediated activation.
DR   Reactome; R-HSA-445144; Signal transduction by L1.
DR   Reactome; R-HSA-5210891; Uptake and function of anthrax toxins.
DR   Reactome; R-HSA-5673000; RAF activation.
DR   Reactome; R-HSA-5674135; MAP2K and MAPK activation.
DR   Reactome; R-HSA-5674499; Negative feedback regulation of MAPK pathway.
DR   Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802952; Signaling by BRAF and RAF1 fusions.
DR   Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF.
DR   Reactome; R-HSA-9649948; Signaling downstream of RAS mutants.
DR   Reactome; R-HSA-9652169; Signaling by MAP2K mutants.
DR   Reactome; R-HSA-9656223; Signaling by RAF1 mutants.
DR   SignaLink; P36507; -.
DR   SIGNOR; P36507; -.
DR   BioGRID-ORCS; 5605; 24 hits in 1108 CRISPR screens.
DR   ChiTaRS; MAP2K2; human.
DR   EvolutionaryTrace; P36507; -.
DR   GeneWiki; MAP2K2; -.
DR   GenomeRNAi; 5605; -.
DR   Pharos; P36507; Tclin.
DR   PRO; PR:P36507; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; P36507; protein.
DR   Bgee; ENSG00000126934; Expressed in mucosa of transverse colon and 200 other tissues.
DR   ExpressionAtlas; P36507; baseline and differential.
DR   Genevisible; P36507; HS.
DR   GO; GO:0005911; C:cell-cell junction; IDA:UniProtKB.
DR   GO; GO:0009898; C:cytoplasmic side of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:UniProtKB.
DR   GO; GO:0005769; C:early endosome; TAS:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; NAS:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; TAS:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0005770; C:late endosome; TAS:UniProtKB.
DR   GO; GO:0005874; C:microtubule; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; TAS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; TAS:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005778; C:peroxisomal membrane; HDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004708; F:MAP kinase kinase activity; IDA:UniProtKB.
DR   GO; GO:0005078; F:MAP-kinase scaffold activity; IMP:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0030165; F:PDZ domain binding; IDA:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0043539; F:protein serine/threonine kinase activator activity; IDA:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; TAS:Reactome.
DR   GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; TAS:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0097110; F:scaffold protein binding; IPI:UniProtKB.
DR   GO; GO:0060502; P:epithelial cell proliferation involved in lung morphogenesis; IEA:Ensembl.
DR   GO; GO:0070371; P:ERK1 and ERK2 cascade; IMP:BHF-UCL.
DR   GO; GO:0060324; P:face development; IEA:Ensembl.
DR   GO; GO:0007507; P:heart development; IEA:Ensembl.
DR   GO; GO:0000165; P:MAPK cascade; IBA:GO_Central.
DR   GO; GO:0036289; P:peptidyl-serine autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0050772; P:positive regulation of axonogenesis; IEA:Ensembl.
DR   GO; GO:2000147; P:positive regulation of cell motility; IEA:Ensembl.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; IMP:BHF-UCL.
DR   GO; GO:1903800; P:positive regulation of miRNA maturation; IMP:BHF-UCL.
DR   GO; GO:0071902; P:positive regulation of protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0048679; P:regulation of axon regeneration; IEA:Ensembl.
DR   GO; GO:2000641; P:regulation of early endosome to late endosome transport; TAS:UniProtKB.
DR   GO; GO:0090170; P:regulation of Golgi inheritance; TAS:UniProtKB.
DR   GO; GO:0032872; P:regulation of stress-activated MAPK cascade; TAS:UniProtKB.
DR   GO; GO:0048538; P:thymus development; IEA:Ensembl.
DR   GO; GO:0030878; P:thyroid gland development; IEA:Ensembl.
DR   GO; GO:0060440; P:trachea formation; IEA:Ensembl.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; ATP-binding; Cardiomyopathy; Cytoplasm;
KW   Direct protein sequencing; Disease variant; Ectodermal dysplasia;
KW   Intellectual disability; Kinase; Magnesium; Membrane; Metal-binding;
KW   Nucleotide-binding; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Tyrosine-protein kinase.
FT   CHAIN           1..400
FT                   /note="Dual specificity mitogen-activated protein kinase
FT                   kinase 2"
FT                   /id="PRO_0000086372"
FT   DOMAIN          72..369
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          286..310
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        194
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         78..86
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         101
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   SITE            10..11
FT                   /note="Cleavage; by anthrax lethal factor"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0007744|PubMed:19413330"
FT   MOD_RES         23
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         222
FT                   /note="(Microbial infection) O-acetylserine; by Yersinia
FT                   YopJ; alternate"
FT                   /evidence="ECO:0000269|PubMed:17116858"
FT   MOD_RES         222
FT                   /note="Phosphoserine; by RAF; alternate"
FT                   /evidence="ECO:0000269|PubMed:10409742,
FT                   ECO:0000269|PubMed:17116858"
FT   MOD_RES         226
FT                   /note="(Microbial infection) O-acetylserine; by Yersinia
FT                   YopJ; alternate"
FT                   /evidence="ECO:0000269|PubMed:17116858"
FT   MOD_RES         226
FT                   /note="Phosphoserine; alternate"
FT                   /evidence="ECO:0000269|PubMed:17116858"
FT   MOD_RES         293
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         295
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         306
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q02750"
FT   MOD_RES         394
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|Ref.3, ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         396
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   VARIANT         57
FT                   /note="F -> C (in CFC4; dbSNP:rs121434497)"
FT                   /evidence="ECO:0000269|PubMed:16439621"
FT                   /id="VAR_035095"
FT   VARIANT         57
FT                   /note="F -> V (in CFC4; dbSNP:rs121434498)"
FT                   /evidence="ECO:0000269|PubMed:18042262"
FT                   /id="VAR_069781"
FT   VARIANT         128
FT                   /note="P -> Q (in CFC4; results in increased kinase
FT                   activity; dbSNP:rs267607230)"
FT                   /evidence="ECO:0000269|PubMed:20358587"
FT                   /id="VAR_069782"
FT   VARIANT         134
FT                   /note="Y -> H (in CFC4; dbSNP:rs121434499)"
FT                   /evidence="ECO:0000269|PubMed:18042262"
FT                   /id="VAR_069783"
FT   CONFLICT        56
FT                   /note="A -> R (in Ref. 6; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   HELIX           69..71
FT                   /evidence="ECO:0007829|PDB:1S9I"
FT   STRAND          72..80
FT                   /evidence="ECO:0007829|PDB:1S9I"
FT   STRAND          85..91
FT                   /evidence="ECO:0007829|PDB:1S9I"
FT   TURN            92..94
FT                   /evidence="ECO:0007829|PDB:1S9I"
FT   STRAND          97..103
FT                   /evidence="ECO:0007829|PDB:1S9I"
FT   HELIX           110..119
FT                   /evidence="ECO:0007829|PDB:1S9I"
FT   HELIX           120..122
FT                   /evidence="ECO:0007829|PDB:1S9I"
FT   STRAND          133..148
FT                   /evidence="ECO:0007829|PDB:1S9I"
FT   HELIX           155..161
FT                   /evidence="ECO:0007829|PDB:1S9I"
FT   STRAND          162..164
FT                   /evidence="ECO:0007829|PDB:1S9I"
FT   HELIX           167..186
FT                   /evidence="ECO:0007829|PDB:1S9I"
FT   HELIX           197..199
FT                   /evidence="ECO:0007829|PDB:1S9I"
FT   STRAND          200..202
FT                   /evidence="ECO:0007829|PDB:1S9I"
FT   STRAND          208..210
FT                   /evidence="ECO:0007829|PDB:1S9I"
FT   HELIX           217..222
FT                   /evidence="ECO:0007829|PDB:1S9I"
FT   HELIX           236..239
FT                   /evidence="ECO:0007829|PDB:1S9I"
FT   HELIX           246..262
FT                   /evidence="ECO:0007829|PDB:1S9I"
FT   HELIX           272..279
FT                   /evidence="ECO:0007829|PDB:1S9I"
FT   HELIX           318..327
FT                   /evidence="ECO:0007829|PDB:1S9I"
FT   TURN            335..337
FT                   /evidence="ECO:0007829|PDB:1S9I"
FT   HELIX           340..349
FT                   /evidence="ECO:0007829|PDB:1S9I"
FT   TURN            354..356
FT                   /evidence="ECO:0007829|PDB:1S9I"
FT   HELIX           360..364
FT                   /evidence="ECO:0007829|PDB:1S9I"
FT   HELIX           367..374
FT                   /evidence="ECO:0007829|PDB:1S9I"
FT   HELIX           379..386
FT                   /evidence="ECO:0007829|PDB:1S9I"
SQ   SEQUENCE   400 AA;  44424 MW;  3401D522515C30A5 CRC64;
     MLARRKPVLP ALTINPTIAE GPSPTSEGAS EANLVDLQKK LEELELDEQQ KKRLEAFLTQ
     KAKVGELKDD DFERISELGA GNGGVVTKVQ HRPSGLIMAR KLIHLEIKPA IRNQIIRELQ
     VLHECNSPYI VGFYGAFYSD GEISICMEHM DGGSLDQVLK EAKRIPEEIL GKVSIAVLRG
     LAYLREKHQI MHRDVKPSNI LVNSRGEIKL CDFGVSGQLI DSMANSFVGT RSYMAPERLQ
     GTHYSVQSDI WSMGLSLVEL AVGRYPIPPP DAKELEAIFG RPVVDGEEGE PHSISPRPRP
     PGRPVSGHGM DSRPAMAIFE LLDYIVNEPP PKLPNGVFTP DFQEFVNKCL IKNPAERADL
     KMLTNHTFIK RSEVEEVDFA GWLCKTLRLN QPGTPTRTAV
//
